Objective: To confirm the retention rate of ketogenic diet therapy (KDT) in children with drug‐resistant epilepsy and identify its related factors through a cohort analysis. Methods: This was a single‐center cohort study. Baseline data were collected, and regular follow‐up was conducted after KDT treatment. The retention rate of KDT at different time points was determined. Cox regression analyses and other statistical methods were used to identify the factors related to the retention rate. Results: A total of 337 patients were included. 43.3% (146/337) of the patients had only spasms, 16.9% (57/337) had a genetic etiology, and 14.0% (47/337) had a structural etiology. Overall, 51.9% (175/337) of the patients were classified as having infantile epileptic spasm syndrome. The median age at KDT initiation was 33 months. 38.3% (129/337) of the patients responded to KDT. The retention rate of KDT at 3, 6, 12 and 24 months were 86.6% (292/337), 62.6% (211/337), 35.0% (118/337), and 20.2% (68/337), respectively. 9.9% (56/282) stopped the treatment due to unsatisfactory seizure control and 54.6% (154/282) stopped due to a non‐response. The retention rate in patients who responded to KDT was relatively greater than that in patients who did not respond to KDT [HR: 4.714 (95% CI: 3.493, 6.362), p < 0.001]. The retention rate of KDT at 3 months was associated with seizure type and anti‐seizure efficacy. The retention rate of KDT at 6 months was associated with seizure type, status epilepticus and anti‐seizure efficacy. The retention rate of KDT at 12 and 24 months were both associated with anti‐seizure efficacy. Significance: Anti‐seizure efficacy was the sole independent predictor of long‐term retention. This large‐scale cohort study advances the field by demonstrating the predominant role of efficacy in long‐term adherence. The cohort size ( N = 337), one of the largest reported, strengthens evidence that the long‐term retention rate (>1 year) can be used as an important indicator to evaluate the efficacy of KDT, which is simple and reliable.
Background: 5q spinal muscular atrophy (SMA) is a hereditary neuromuscular disorder characterized by progressive muscle weakness. Nusinersen, the first disease-modifying therapy for SMA, has demonstrated efficacy in both clinical trials and real-world studies. However, the precise timing of therapeutic onset following Nusinersen administration remains unclear. Methods: This retrospective study analyzed clinical data from patients with genetically confirmed 5q SMA who received Nusinersen treatment for at least six months at Peking University First Hospital. Motor function was assessed using standardized scales prior to each dose. Results: In total, 74 patients were screened, of whom 62 were enrolled, including 14 with type 1, 29 with type 2, and 19 with type 3 SMA. Thirty-two patients completed motor function assessments. After six months of treatment, 62.5% achieved a primary clinically meaningful response (an increase of ≥4 points in CHOP-INTEND or ≥3 points in HFMSE). Seven patients (21.9%) attained or regained motor milestones. Median improvements were 6 points in CHOP-INTEND (p = 0.001), 4 points in HFMSE (p = 0.003), and 1.5 points in RULM (p = 0.045). Further analysis indicated that the available median time to treatment response was approximately 2 months. In patients with severe scoliosis or prior spinal surgery, ultrasound-guided lumbar puncture demonstrated a high success rate (94.9%). Regarding safety, intrathecal injection-related adverse events occurred in eight patients (12.9%), and no adverse events led to treatment discontinuation. Conclusions: During the loading phase, Nusinersen provides clinical benefit for the majority of patients, with a median time to therapeutic response for monitoring of approximately 2 months. Ultrasound-guided intrathecal administration is the preferred approach for individuals with complicated spinal conditions. These findings may help guide clinical expectations for physicians, patients, and caregivers.